Tepotinib

What is Tepotinib?

Tepotinib is a prescription medication used in oncology, specifically as a **targeted therapy** for certain types of cancer. It is an oral **protein kinase inhibitor** that works by targeting specific molecular pathways involved in cancer growth. The primary indication for Tepotinib is the treatment of adult patients with metastatic **non-small cell lung cancer (NSCLC)** that harbors **MET exon 14 skipping alterations**. This specific genetic mutation is a biomarker that identifies patients who are most likely to benefit from this innovative treatment. Tepotinib is known by its brand name, TEPMETKO, and represents a significant advancement in personalized medicine for lung cancer patients who have this particular genetic signature.

Before initiating treatment with Tepotinib, patients must undergo diagnostic testing to confirm the presence of MET exon 14 skipping alterations. This ensures that the medication is prescribed to individuals for whom it is most likely to be effective, aligning with the principles of precision oncology. Tepotinib offers a crucial treatment option for patients whose cancer has progressed on or after prior platinum-based chemotherapy, or for those who are unable to receive platinum-based chemotherapy.

How Does Tepotinib Work?

The mechanism of action of Tepotinib is centered on its ability to selectively inhibit the activity of the **MET receptor tyrosine kinase**. The MET protein, encoded by the MET gene, plays a vital role in cell growth, survival, and proliferation. In certain cancers, including a subset of NSCLC, the MET pathway can become overactive or dysregulated, often due to genetic alterations like MET exon 14 skipping. This dysregulation leads to uncontrolled cell growth and tumor progression.

Tepotinib works by binding to and inhibiting the MET receptor, thereby blocking the downstream signaling pathways that promote cancer cell proliferation and survival. By selectively targeting this altered pathway, Tepotinib helps to shrink tumors and slow the progression of the disease, while minimizing damage to healthy cells that do not overexpress or have altered MET pathways. This targeted approach is what distinguishes Tepotinib from traditional chemotherapy, which often affects rapidly dividing cells indiscriminately. The specificity of Tepotinib helps to improve treatment efficacy and potentially reduce certain side effects.

Medical Uses of Tepotinib

The primary medical use of Tepotinib is in the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has specific genetic alterations. Specifically, it is approved for patients whose tumors have MET exon 14 skipping alterations. This condition can be identified through a companion diagnostic test, which is crucial before prescribing the drug.

• Metastatic NSCLC with MET Exon 14 Skipping Alterations: Tepotinib is indicated for patients whose cancer has spread to other parts of the body (metastatic) and has this particular genetic mutation. It is typically used in patients who have either received prior systemic therapy or who are unable to receive standard chemotherapy.
• First-line or Subsequent Therapy: Depending on regulatory approvals in different regions and individual patient circumstances, Tepotinib can be considered as a first-line treatment for newly diagnosed patients with this specific biomarker, or as a subsequent therapy for those whose disease has progressed after other treatments.

The identification of MET exon 14 skipping alterations through advanced molecular testing is paramount, as only patients with this specific biomarker are expected to respond to Tepotinib. This underscores the importance of precision medicine in modern oncology, where treatments are tailored to the unique genetic profile of a patient's tumor.

Tepotinib Dosage and Administration

Tepotinib is an oral medication, typically taken once daily. Adherence to the prescribed dosage and administration instructions is crucial for maximizing its effectiveness and managing potential side effects.

• Standard Dosage: The recommended dose of Tepotinib is usually 500 mg (two 250 mg tablets) taken orally once daily.
• Administration: It is imperative to take Tepotinib with food. Taking it with food helps to increase its absorption and can reduce the incidence of gastrointestinal side effects. The tablets should be swallowed whole and not crushed, chewed, or split.
• Missed Dose: If a dose is missed, patients should not take an extra dose to make up for it. They should take the next scheduled dose at their regular time.
• Dose Modifications: Your healthcare provider may adjust the dose of Tepotinib based on your response to treatment and the occurrence of side effects. It is important not to change your dose or stop taking the medication without consulting your doctor. Regular monitoring and communication with your healthcare team are essential throughout the treatment period.

Patients should always follow the specific instructions provided by their prescribing physician and pharmacist regarding the dosage and administration of Tepotinib.

Potential Side Effects of Tepotinib

Like all medications, Tepotinib can cause side effects. While not everyone experiences them, and their severity can vary, it's important to be aware of potential adverse reactions. Patients should report any new or worsening symptoms to their healthcare provider promptly.

Common Side Effects:

• Peripheral edema: Swelling, particularly in the ankles, feet, or hands, is a very common side effect.
• Nausea and vomiting
• Diarrhea
• Fatigue or weakness
• Increased blood creatinine levels
• Abnormal liver function tests (e.g., increased AST, ALT)
• Shortness of breath
• Decreased appetite

Serious Side Effects:

• Interstitial Lung Disease (ILD) / Pneumonitis: This is a serious and potentially life-threatening lung condition. Symptoms can include new or worsening cough, shortness of breath, and fever. Patients experiencing these symptoms should seek immediate medical attention.
• Hepatotoxicity: Severe liver problems can occur. Regular monitoring of liver function tests is crucial during treatment.
• Embryo-Fetal Toxicity: Tepotinib can cause harm to a fetus. Pregnant women or women who could become pregnant should avoid taking this medication. Effective contraception is advised for both males and females during treatment and for a specified period after the last dose.
• Pancreatic effects: Elevations in amylase and lipase have been observed.

This is not a complete list of all possible side effects. Always discuss any concerns with your doctor, who can provide a comprehensive overview and strategies for managing side effects.

Tepotinib Drug Interactions

Tepotinib can interact with other medications, potentially altering their effectiveness or increasing the risk of side effects. It is crucial to inform your healthcare provider about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are taking before starting Tepotinib.

Key Drug Interactions:

• CYP3A4 Inhibitors and Inducers: Tepotinib is metabolized by the enzyme CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase Tepotinib exposure, potentially leading to increased side effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Tepotinib exposure, reducing its effectiveness. Dose adjustments or alternative medications may be necessary.
• P-glycoprotein (P-gp) Substrates: Tepotinib is an inhibitor of P-gp. Co-administration with P-gp substrates (e.g., digoxin, dabigatran etexilate) can increase the concentrations of these drugs, potentially leading to increased toxicity. Careful monitoring and dose adjustments of the P-gp substrate may be required.
• Acid-Reducing Agents: Medications that reduce stomach acid, such as proton pump inhibitors (PPIs), H2-receptor blockers, and antacids, can affect the absorption of Tepotinib. It is generally recommended to avoid concomitant use or to administer Tepotinib separately from these agents as directed by a physician.

Always review your complete medication list with your doctor or pharmacist to identify and manage potential drug interactions effectively.

Frequently Asked Questions About Tepotinib

Is Tepotinib a chemotherapy drug?

No, Tepotinib is not a traditional chemotherapy drug. It is a targeted therapy, specifically a protein kinase inhibitor, that works by targeting specific genetic alterations (MET exon 14 skipping) in cancer cells, rather than broadly attacking rapidly dividing cells like conventional chemotherapy.

How is Tepotinib taken?

Tepotinib is an oral medication taken as tablets. It is typically prescribed as 500 mg (two 250 mg tablets) once daily, and it must be taken with food to ensure proper absorption.

What type of cancer does Tepotinib treat?

Tepotinib is approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has MET exon 14 skipping alterations.

How long do I need to take Tepotinib?

Tepotinib treatment typically continues as long as the patient is benefiting from the therapy and can tolerate the side effects. The duration of treatment is determined by your healthcare provider based on your response to the medication and your overall health.

What are MET exon 14 skipping alterations?

MET exon 14 skipping alterations are specific genetic mutations in the MET gene that lead to an overactive MET protein. This overactivity drives uncontrolled cancer cell growth and survival, making it a target for drugs like Tepotinib.

Products containing Tepotinib are available through trusted online pharmacies. You can browse Tepotinib-based medications at ShipperVIP or Medicenter.

Summary: The Role of Tepotinib in Cancer Treatment

Tepotinib represents a significant advancement in the treatment landscape for non-small cell lung cancer (NSCLC), particularly for patients whose tumors harbor specific MET exon 14 skipping alterations. As a targeted therapy, it offers a precision medicine approach, selectively inhibiting the dysregulated MET pathway to halt cancer progression and shrink tumors.

Its oral administration provides convenience for patients, while its distinct mechanism of action offers a valuable alternative to traditional chemotherapy. However, like all potent medications, Tepotinib comes with a profile of potential side effects, some of which can be serious, and it requires careful management of drug interactions. Patient selection through biomarker testing is critical to ensure optimal outcomes and minimize unnecessary exposure. Ongoing research continues to explore the full potential of Tepotinib and similar targeted agents, promising a future with more personalized and effective cancer therapies.